NCT06017609: An ongoing trial by Akros Pharma Inc.
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06017609 |
|---|---|
| Title | A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of JTT-861 Administered for 12 Weeks in Subjects With Heart Failure With Reduced Ejection Fraction |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 20, 2023 |
| Completion date | Aug. 31, 2026 |
| Required reporting date | Aug. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |